Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study
- PMID: 1989916
- DOI: 10.1016/0090-8258(91)90086-k
Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study
Abstract
Between June 20, 1977 and February 5, 1983, the Gynecologic Oncology Group entered 1180 women with clinical stage I or II (occult) endometrial carcinoma into a surgical-pathological staging study. Eight hundred ninety-five patients with endometrioid or adenosquamous carcinoma were evaluable for this study which relates surgical-pathological parameters and postoperative treatment to recurrence-free interval and recurrence site. Proportional hazards modeling of time to recurrence was performed. For patients without metastasis determined by surgical-pathological staging the greatest determinant of recurrence was grade 3 histology adenocarcinoma grade 3, relative risk (RR) = 15; adenosquamous carcinoma grade 3, RR = 8.1; all adenocanthomas, RR = 1.0). Of 48 patients with histologically documented aortic node metastases, 47 had one or more of the following features: (1) grossly positive pelvic nodes, (2) grossly positive adnexal metastasis, or (3) outer one-third myometrial invasion. Pelvic radiation was administered to 48.0% and vaginal brachytherapy alone to 10.2% of patients postoperatively; 41.8% received no adjuvant radiation therapy. None of three recurrences in the vaginal implant group were vaginal or pelvic; 7.4% (7 of 95) of recurrences in the pelvic radiation therapy (RT) group were vaginal and 16.8% were pelvic; 18.2% (8 of 44) of recurrences in the no adjuvant radiation group were vaginal and 31.8% pelvic. Because of the high degree of selection bias no valid comparisons can be made of recurrence-free interval in these groups. The 5-year recurrence-free interval for patients with negative surgical-pathological risk factors (other than grade and myoinvasion) was 92.7%; involvement of the isthmus/cervix 69.8%; positive pelvic cytology 56.0%; vascular space invasion 55.0%; pelvic node or adnexal metastases 57.8%; and aortic node metastases or gross laparotomy findings 41.2%. It is not clear that cervix invasion per se diminishes survival, because it is more often associated with poor tumor differentiation (34.7% versus 24.0%, grade 3) and deep myoinvasion (47.0 vs 18.6%) than cases without cervix invasion. The relapse rate among cervix-positive and -negative cases with grade 3 lesions and deep myoinvasion is not dramatically different (48.8% vs 39.8%). The proportion of failures which were vaginal/pelvic (34.6% for the surgery only group compared to 12.5% of the RT group) appears to favor the use of adjuvant radiation for patients with more than one-third myoinvasion and grade 2 or 3 tumor. There were 97 patients in the study group with malignant cytology of which 29.1% had regional/distant failure, which compares to 10.5% of the cytology-negative patients.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1272-6. doi: 10.1016/s0360-3016(02)04404-8. Int J Radiat Oncol Biol Phys. 2003. PMID: 12654437 Review.
-
Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study.Gynecol Oncol. 1990 Feb;36(2):166-71. doi: 10.1016/0090-8258(90)90166-i. Gynecol Oncol. 1990. PMID: 2298404 Clinical Trial.
-
Adenocarcinoma of the endometrium treated with combined irradiation and surgery: study of 437 patients.Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):81-97. doi: 10.1016/s0360-3016(00)01571-6. Int J Radiat Oncol Biol Phys. 2001. PMID: 11316550 Clinical Trial.
-
An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study.Gynecol Oncol. 1996 Dec;63(3):304-11. doi: 10.1006/gyno.1996.0327. Gynecol Oncol. 1996. PMID: 8946863 Clinical Trial.
-
[Endometrial cancer: what's new?].Gynecol Obstet Fertil. 2003 Jul-Aug;31(7-8):581-96. doi: 10.1016/s1297-9589(03)00173-5. Gynecol Obstet Fertil. 2003. PMID: 14563602 Review. French.
Cited by
-
Intensity-modulated vaginal brachytherapy applicator and single- and multi-channel applicators in vaginal cuff brachytherapy.J Contemp Brachytherapy. 2024 Apr;16(2):132-138. doi: 10.5114/jcb.2024.138979. Epub 2024 Apr 18. J Contemp Brachytherapy. 2024. PMID: 38808211 Free PMC article.
-
Efficacy of Single- and Dual-Docking Robotic Surgery of Paraaortic and Pelvic Lymphadenectomy in High-Risk Endometrial Cancer.J Pers Med. 2024 Apr 23;14(5):441. doi: 10.3390/jpm14050441. J Pers Med. 2024. PMID: 38793024 Free PMC article.
-
High-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment Options.Reprod Sci. 2024 Apr 24. doi: 10.1007/s43032-024-01544-5. Online ahead of print. Reprod Sci. 2024. PMID: 38658487 Review.
-
Emerging Advances in Endometrial Cancer: Integration of Molecular Classification into Staging for Enhanced Prognostic Accuracy and Implications for Racial Disparities.Cancers (Basel). 2024 Mar 16;16(6):1172. doi: 10.3390/cancers16061172. Cancers (Basel). 2024. PMID: 38539507 Free PMC article. Review.
-
Detection of metastatic lymph node and sentinel lymph node mapping using mannose receptor targeting in in vivo mouse footpad tumor models and rabbit uterine cancer models.Int J Surg. 2024 May 1;110(5):2692-2700. doi: 10.1097/JS9.0000000000001227. Int J Surg. 2024. PMID: 38377062 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical